Figure 4 | Scientific Reports

Figure 4

From: Novel VEGFR2 inhibitors with thiazoloquinoxaline scaffold targeting hepatocellular carcinoma with lower cardiotoxic impact

Figure 4

Effect of daily treatment (3 days) of sorafenib or compound 4d [50 mg/ kg, p.o] on serum lactate dehydrogenase (LDH, IU/ml) and Catalase activity (IU/ml) in 8 Gy irradiated mice. All values are plotted as mean ± S.E. * represented significance from Normal at P ≤ 0.05, # represented significance from IRR at P ≤ 0.05, s represented significance from IRR + sorafenib at P ≤ 0.05.

Back to article page